S. Sherman Jeffrey's Insider Trades & SAST Disclosures
S. Sherman Jeffrey's most recent trade in Neogenomics Inc. was a trade of 20,000 Common Stock done at an average price of $7.5 . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern S. Sherman Jeffrey.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 7.51 per share. | 02 May 2025 | 20,000 | 158,494 (0%) | 0% | 7.5 | 150,104 | Common Stock |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 214,900 | 214,900 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 126,476 | 126,476 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 15,535 | 31,071 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 15,535 | 141,271 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 4,207 | 137,064 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 07 Dec 2024 | 11,746 | 123,754 (0%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 50,000 | 164,380 (0%) | 0% | 0 | Common Stock | |
| Larimar Therapeutics Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 138,667 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 26,011 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 148,505 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 26,011 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 138,667 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 3,167 | 135,500 (0%) | 0% | 14.9 | 47,062 | Common Stock |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 3,167 | 135,500 (0%) | 0% | 14.9 | 47,062 | Common Stock |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Other type of transaction at price $ 0.00 per share. | 15 Mar 2024 | 6,502 | 114,380 (0%) | 0% | - | Common Stock | |
| Neogenomics Inc. | Sherman Jeffrey S. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 77,913 | 77,913 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | S. Sherman Jeffrey | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 46,606 | 46,606 | - | - | Performance Stock Unit | |
| Neogenomics Inc. | S. Jeffrey Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 46,606 | 46,606 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Jeffrey Sherman S. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 07 Dec 2023 | 8,147 | 125,662 (0%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 42,500 | 107,878 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 73,016 | 73,016 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 39,016 | 39,016 | - | - | Performance Stock Unit | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 39,016 | 39,016 | - | - | Restricted Stock Unit | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Jan 2023 | 33,795 | 2,376 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Jan 2023 | 33,795 | 83,109 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.05 per share. | 10 Jan 2023 | 3,368 | 39,539 (0%) | 0% | 113.0 | 380,752 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.10 per share. | 10 Jan 2023 | 3,368 | 36,171 (0%) | 0% | 113.1 | 380,921 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 51,132 | 65,562 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.24 per share. | 04 Jan 2023 | 22,655 | 42,907 (0%) | 0% | 113.2 | 2,565,452 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 18,397 | 18,397 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 12,095 | 0 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 9,318 | 4,654 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 9,314 | 9,314 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 7,257 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 6,348 | 12,696 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.29 per share. | 04 Jan 2023 | 5,187 | 49,314 (0%) | 0% | 113.3 | 587,635 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 4,834 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 1,966 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 21,772 | 24,147 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 21,772 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.80 per share. | 01 Jan 2023 | 9,717 | 14,430 (0%) | 0% | 113.8 | 1,105,795 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 21,772 | 21,772 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 13,972 | 13,972 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 111.45 per share. | 12 Dec 2022 | 21,378 | 84,430 (0%) | 0% | 111.4 | 2,382,484 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2022 | 8,531 | 61,475 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2022 | 8,531 | 2,375 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 111.44 per share. | 12 Dec 2022 | 6,974 | 54,501 (0%) | 0% | 111.4 | 777,208 | Ordinary Shares |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 249,169 | 249,169 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 89,206 | 133,809 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 44,603 | 44,603 (0%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 15,000 | 65,378 (0%) | 0% | 0 | Common Stock | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 110.02 per share. | 06 Apr 2022 | 42,009 | 10,629 (0%) | 0% | 110.0 | 4,621,872 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 12,304 | 50,062 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 12,304 | 46,989 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2022 | 8,531 | 164,469 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.14 per share. | 18 Mar 2022 | 8,531 | 52,638 (0%) | 0% | 22.1 | 188,876 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 8,169 | 52,944 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 8,169 | 44,107 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 5,287 | 52,276 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 5,287 | 44,775 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2022 | 5,354 | 0 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2022 | 5,354 | 61,665 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.42 per share. | 21 Jan 2022 | 2,372 | 59,293 (0%) | 0% | 86.4 | 204,988 | Ordinary Shares |
| Privia Health Group Inc | Jeffrey S. Sherman | EVP, CFO and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 235,128 | 235,128 | - | - | Stock Option (Right to Purchase) | |
| Privia Health Group Inc | Jeffrey S. Sherman | EVP, CFO and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 61,307 | 61,307 | - | 0 | Common Stock, $0.01 par value per share | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 52,570 | 61,685 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 04 Jan 2022 | 37,675 | 56,311 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 32,301 | 93,986 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 19,044 | 19,044 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 12,261 | 0 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 12,095 | 12,095 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Jan 2022 | 10,729 | 9,115 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Jan 2022 | 10,729 | 37,808 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 9,678 | 4,834 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 9,314 | 18,628 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 9,222 | 9,223 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Jan 2022 | 50 | 37,758 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2021 | 10,729 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.61 per share. | 27 Oct 2021 | 10,729 | 19,844 (0%) | 0% | 7.6 | 81,648 | Ordinary Shares |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 50,378 | 50,378 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 47,040 | 47,040 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 31,360 | 31,360 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 31,360 | 31,360 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 19,650 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 19,650 | 19,650 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 46,271 | 10,729 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 21 Sep 2021 | 46,271 | 9,115 (0%) | 0% | 110 | 5,089,810 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.61 per share. | 21 Sep 2021 | 46,271 | 55,386 (0%) | 0% | 7.6 | 352,122 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Sep 2021 | 4,042 | 9,115 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Sep 2021 | 4,042 | 27,079 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 14,514 | 14,514 | - | - | Performance Restricted Stock Units (PSUs) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges